Regeneron Pharmaceuticals


Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COV™ (casirivimab with imdevimab) 1,200 mg administered via subcutaneous (SC) administration.


To know more about the story, click right here.

0 comments